Anavex Life Sciences Corp (AVXL)

[ALP7]

New Phase 2 AD study with interesting results:
"randomised, double-blinded, placebo-controlled phase-II clinical trial and studied the effect of CMA administration on the global metabolism of AD patients"

"We showed a significant decrease of AD Assessment Scale-cognitive subscale (ADAS-Cog) score on day 84 vs day 0 (P?=?0.00001, 29% improvement) in the CMA group. Moreover, there was a significant decline (P?=?0.0073) in ADAS-Cog scores (improvement of cognitive functions) in the CMA compared to the placebo group in patients with higher ADAS-Cog scores. Improved cognitive functions in AD patients were supported by the relevant alterations in the hippocampal volumes and cortical thickness based on imaging analysis."

Results are reported in amazing detail: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879258/#MOESM2. Lots of discussion about various MOA.

Will we ever see a report like this from AVXL? As I mentioned before, there are thousands of researchers investigating hundreds of pathways. Would be nice if Missling showed a sense of urgency in releasing the Phase 2b/3 data.